1. Cadre conceptuel général de la recherche
1.2. Émergence et évolution de l’arbitrage commercial
1.2.1. Développement de la compétence de l’arbitre en matière de
1.2.1.1. La phase initiale d'évolution de la compétence de l’arbitre en
1. MOREIRA, M. M., Envelhecimento da população brasileira: aspectos gerais. In: WONG, I. R. org. O envelhecimento da população brasileira e o aumento da longevidade – subsídios para políticas orientadas ao bem estar do idoso. Belo Horizonte: UFMG/CEDEPLAR: ABEP, p. 25-56, 2000.
2. CARVALHO, J. A. M.; GARCIA, R. A. O envelhecimento da população brasileira: um enfoque demográfico. Cad. Saúde Pública, v. 19, n. 3, p. 725-733, 2003.
3. IBGE – Instituto Brasileiro de Geografia e Estatística. Projeção da população do Brasil por sexo e idade - 1980–2050: revisão 2008. Rio de Janeiro: IBGE – Depis. Disponível em: <http://www. ibge.gov.br>. Acesso em: 17 maio 2009.
4. PERLS, T.; KUNKEL, L. M.; PUCA, A. A. The genetics of exceptional human longevity. J Am Geriatr Soc, v. 50, n. 2, p. 359-68, 2002.
5. CHRISTENSEN, K.; JOHNSON, T. E.; VAUPEL, J. W. The quest for genetic determinants of human longevity: challenges and insights. Nat Rev Genet, v. 7, n. 6, p. 436-48, 2006.
6. PAWELEC, G. et al. T cells and aging (update february 1999). Front Biosci, v. 4, n. p. D216-69, 1999.
7. FRANCESCHI, C. et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci, n. 908, p. 244-54, jun, 2000.
8. BRUUNSGAARD, H.; PEDERSEN, M.; PEDERSEN, B. K. Aging and proinflammatory cytokines. Curr Opin Hematol, v. 8, n. 3, p. 131-6, 2001.
9. TARAZONA, R. et al. Basic biology and clinical impact of immunosenescence. Exp Gerontol, v. 37, n. 2-3, p. 183-9, jan, 2002.
10. MAKINODAN, T.; KAY, M. M. Age influence on the immune system. Adv Immunol, v. 29, p. 287-330, 1980.
11. MURASKO, D. M.; WEINER, P.; KAYE, D. Decline in mitogen induced proliferation of lymphocytes with increasing age. Clin Exp Immunol, v. 70, n. 2, p. 440-8, 1987.
12. FRANCESCHI, C. et al. The immunology of exceptional individuals: the lesson of centenarians. Immunol Today, v. 16, n. 1, p. 12-6, 1995.
13. GRIMBLE, R. F. Inflammatory response in the elderly. Curr Opin Clin Nutr Metab Care, v. 6, n. 1, p. 21-9, 2003.
14. SALMENNIEMI, U. et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation, v. 110, n. 25, p. 3842-8, 2004. 15. STRAUB, R. H. et al. Cytokines and hormones as possible links between
endocrinosenescence and immunosenescence. J Neuroimmunol, v. 109, n. 1, p. 10-5, 2000.
16. AUERNHAMMER, C. J.; MELMED, S. Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr Rev, v. 21, n. 3, p. 313-45, 2000.
17. MURPHY, K. M. et al. Signaling and transcription in T helper development. Annu Rev Immunol, v. 18, p. 451-94, april, 2000.
18. FORSEY, R. J. et al. Plasma cytokine profiles in elderly humans. Mech Ageing Dev, v. 124, n. 4, p. 487-93, 2003.
19. CHENG, X. et al. TH1/TH2 functional imbalance after acute myocardial infarction: coronary arterial inflammation or myocardial inflammation. J Clin Immunol, v. 25, n. 3, p. 246-53, 2005.
20. PASQUI, A. L. et al. Cytokines in acute coronary syndromes. Int J Cardiol, v. 105, n. 3, p. 355-6, 2005.
21. STEPPICH, B. A. et al. Cytokine profiles and T cell function in acute coronary syndromes. Atherosclerosis, v. 190, n. 2, p. 443-51, 2007.
22. LIO, D. et al. Allele frequencies of +874T-->A single nucleotide polymorphism at the first intron of interferon-gamma gene in a group of Italian centenarians. Exp Gerontol, v. 37, n. 2-3, p. 315-9, 2002.
23. BIDWELL, J. et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun, v. 1, n. 1, p. 3-19, 1999.
24. BIDWELL, J. et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun, v. 2, n. 2, p. 61-70, 2001.
25. FRANCESCHI, C.; BONAFE, M.; VALENSIN, S. Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine, v. 18, n. 16, p. 1717-20, 2000.
26. LUZ, C. et al. Impact of psychological and endocrine factors on cytokine production of healthy elderly people. Mech Ageing Dev, v. 124, n. 8-9, p. 887-95, 2003.
27. FULOP, T. et al. Cytokine receptor signalling and aging. Mech Ageing Dev, v. 127, n. 6, p. 526-37, 2006.
28. BIASUCCI, L. M. et al. The variable role of inflammation in acute coronary syndromes and in restenosis. Semin Interv Cardiol, v. 4, n. 3, p. 105-10, 1999.
29. RIDKER, P. M. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. Circulation, v. 105, n. 1, p. 2-4, 2002.
30. VAN DEN BIGGELAAR, A. H. et al. Impaired innate immunity predicts frailty in old age. The Leiden 85-plus study. Exp Gerontol, v. 39, n. 9, p. 1407-14, 2004.
31. BLALOCK, J. E. The syntax of immune-neuroendocrine communication. Immunol Today, v. 15, n. 11, p. 504-11, 1994.
32. JABLONS, D. M. et al. IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. J Immunol, v. 142, n. 5, p. 1542-7, 1989.
33. MASTORAKOS, G.; CHROUSOS, G. P.; WEBER, J. S. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab, v. 77, n. 6, p. 1690-4, 1993.
34. SPATH-SCHWALBE, E. et al. Interleukin-6 stimulates the hypothalamus-pituitary- adrenocortical axis in man. J Clin Endocrinol Metab, v. 79, n. 4, p. 1212-4, 1994. 35. TSIGOS, C. et al. Dose effects of recombinant human interleukin-6 on pituitary
hormone secretion and energy expenditure. Neuroendocrinology, v. 66, n. 1, p. 54-62, 1997.
36. CHELEUITTE, D.; MIZUNO, S.; GLOWACKI, J. In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. J Clin Endocrinol Metab, v. 83, n. 6, p. 2043-51, 1998.
37. STRAUB, R. H. et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab, v. 83, n. 6, p. 2012-7, 1998.
38. KANDA, N.; TSUCHIDA, T.; TAMAKI, K. Testosterone inhibits immunoglobulin production by human peripheral blood mononuclear cells. Clin Exp Immunol, v. 106, n. 2, p. 410-5, 1996.
39. RALSTON, S. H.; RUSSELL, R. G.; GOWEN, M. Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J Bone Miner Res, v. 5, n. 9, p. 983-8, 1990.
40. FERNANDEZ-REAL, J. M. Genetic predispositions to low-grade inflammation and type 2 diabetes. Diabetes Technol Ther, v. 8, n. 1, p. 55-66, 2006.
41. WILDER, R. L. Neuroendocrine-immune system interactions and autoimmunity. Annu Rev Immunol, v. 13, p. 307-38, april, 1995.
42. OSTAN, R. et al. Immunosenescence and immunogenetics of human longevity. Neuroimmunomodulation, v. 15, n. 4-6, p. 224-40, 2008.
43. PAOLISSO, G. et al. Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol, v. 275, n. 2, p. E294-9, 1998.
44. HUANG, H.; PATEL, D. D.; MANTON, K. G. The immune system in aging: roles of cytokines, T cells and NK cells. Front Biosci, v. 10, p. 192-215, jan 1, 2005.
45. MOORADIAN, A. D. et al. Lack of an association between the presence of tumor necrosis factor or interleukin-1 alpha in the blood and weight loss among elderly patients. J Am Geriatr Soc, v. 38, n. 4, p. 397-401, 1990.
46. BRUUNSGAARD, H. et al. Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol, v. 132, n. 1, p. 24-31, 2003. 47. BAUTISTA, L. E. et al. Independent association between inflammatory markers (C-
reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens, v. 19, n. 2, p. 149-54, 2005.
48. MUNOZ, J. et al. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Am J Physiol, v. 276, n. 3, p. G687-93, 1999. 49. GRUNFELD, C.; PALLADINO JUNIOR, M. A. Tumor necrosis factor:
immunologic, antitumor, metabolic, and cardiovascular activities. Adv Intern Med, v. 35, p. 45-71, 1990.
50. FEINGOLD, K. R. et al. Endotoxin, TNF, and IL-1 decrease cholesterol 7 alpha- hydroxylase mRNA levels and activity. J Lipid Res, v. 37, n. 2, p. 223-8, 1996.
51. FEINGOLD, K. R. et al. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. Endocrinology, v. 124, n. 5, p. 2336-42, 1989.
52. SKOOG, T. et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J, v. 23, n. 5, p. 376-83, 2002. 53. SPRIGGS, D. R. et al. Recombinant human tumor necrosis factor administered as a
24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst, v. 80, n. 13, p. 1039-44, 1988.
54. PICKUP, J. C. et al. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci, v. 67, n. 3, p. 291-300, 2000.
55. PAOLISSO, G.; SCHEEN, A.; LEFEBVRE, P. Glucose handling, diabetes and ageing. Horm Res, v. 43, n. 1-3, p. 52-7, 1995.
56. HOTAMISLIGIL, G. S.; SHARGILL, N. S.; SPIEGELMAN, B. M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, v. 259, n. 5091, p. 87-91, 1993.
57. HOTAMISLIGIL, G. S.; SPIEGELMAN, B. M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes, v. 43, n. 11, p. 1271-8, 1994.
58. HOTAMISLIGIL, G. S. et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science, v. 271, n. 5249, p. 665-8, 1996.
59. RUI, L. et al. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest, v. 107, n. 2, p. 181-9, 2001. 60. CARDELLI, M. et al. A genetic-demographic approach reveals male-specific
association between survival and tumor necrosis factor (A/G)-308 polymorphism. J Gerontol A Biol Sci Med Sci, v. 63, n. 5, p. 454-60, 2008.
61. HERRMANN, S. M. et al. Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity. Eur J Clin Invest, v. 28, n. 1, p. 59-66, 1998. 62. PIHLAJAMAKI, J. et al. The effect of the -308A allele of the TNF-alpha gene on
insulin action is dependent on obesity. Obes Res, v. 11, n. 7, p. 912-7, 2003.
63. NICAUD, V. et al. The TNF alpha/G-308A polymorphism influences insulin sensitivity in offspring of patients with coronary heart disease: the European Atherosclerosis Research Study II. Atherosclerosis, v. 161, n. 2, p. 317-25, 2002. 64. CARMELLI, D. et al. The contribution of genetic influences to measures of lower-
extremity function in older male twins. J Gerontol A Biol Sci Med Sci, v. 55, n. 1, p. B49-53, 2000.
65. ANTONICELLI, R. et al. Tumor necrosis factor-alpha gene -308G>A polymorphism is associated with ST-elevation myocardial infarction and with high plasma levels of biochemical ischemia markers. Coron Artery Dis, v. 16, n. 8, p. 489-93, 2005.
66. YOO, C. S. et al. Relationship between iris constitution analysis and TNF-alpha gene polymorphism in hypertensives. Am J Chin Med, v. 35, n. 4, p. 621-9, 2007.
67. VANHALA, M.; KAUTIAINEN, H.; KUMPUSALO, K. Proinflammation and Hypertension: A Population-Based Study. Mediators of Inflammation, v. 2008, p. 1-7, nov, 2008.
68. DALEKOS, G. N. et al. Increased serum levels of interleukin-1beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? J Lab Clin Med, v. 129, n. 3, p. 300-8, 1997. 69. PRICE, S. R.; MIZEL, S. B.; PEKALA, P. H. Regulation of lipoprotein lipase
synthesis and 3T3-L1 adipocyte metabolism by recombinant interleukin 1. Biochim Biophys Acta, v. 889, n. 3, p. 374-81, 1986.
70. MEMON, R. A. et al. Regulation of fatty acid transport protein and fatty acid translocase mRNA levels by endotoxin and cytokines. Am J Physiol, v. 274, n. 2, p. E210-7, 1998.
71. ZHANG, H. H. et al. Dexamethasone inhibits tumor necrosis factor-alpha-induced apoptosis and interleukin-1 beta release in human subcutaneous adipocytes and preadipocytes. J Clin Endocrinol Metab, v. 86, n. 6, p. 2817-25, 2001.
72. DI GIOVINE, F. S. et al. Single base polymorphism at -511 in the human interleukin- 1 beta gene (IL1 beta). Hum Mol Genet, v. 1, n. 6, p. 450, 1992.
73. BIOQUE, G. et al. Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol, v. 102, n. 2, p. 379-83, 1995.
74. POCIOT, F. et al. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest, v. 22, n. 6, p. 396- 402, 1992.
75. POCIOT, F. et al. Genetic susceptibility markers in Danish patients with type 1 (insulin-dependent) diabetes--evidence for polygenicity in man. Danish Study Group of Diabetes in Childhood. Autoimmunity, v. 19, n. 3, p. 169-78, 1994.
76. UM, J. Y. et al. Association of interleukin-1beta gene polymorphism with body mass index in women. Clin Chem, v. 50, n. 3, p. 647-50, 2004.
77. OKAMURA, H. et al. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol, v. 70, p. 281-312, 1998.
78. STEPHENS, J. M.; BUTTS, M. D.; PEKALA, P. H. Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocyte differentiation by tumour necrosis factor-alpha. J Mol Endocrinol, v. 9, n. 1, p. 61-72, 1992.
79. GRACIE, J. A.; ROBERTSON, S. E.; MCINNES, I. B. Interleukin-18. J Leukoc Biol, v. 73, n. 2, p. 213-24, 2003.
80. GERDES, N. et al. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med, v. 195, n. 2, p. 245-57, 2002.
81. FERRUCCI, L. et al. The origins of age-related proinflammatory state. Blood, v. 105, n. 6, p. 2294-9, 2005.
82. GANGEMI, S. et al. Increased circulating Interleukin-18 levels in centenarians with no signs of vascular disease: another paradox of longevity? Exp Gerontol, v. 38, n. 6, p. 669-72, 2003.
83. BLANKENBERG, S. et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation, v. 106, n. 1, p. 24-30, 2002.
84. BLANKENBERG, S. et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation, v. 108, n. 20, p. 2453-9, 2003.
85. YAMAGAMI, H. et al. Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler Thromb Vasc Biol, v. 25, n. 7, p. 1458-62, 2005.
86. ESPOSITO, K. et al. Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab, v. 87, n. 8, p. 3864-6, 2002.
87. OLUSI, S. O.; AL-AWADHI, A.; ABRAHAM, M. Relations of serum interleukin 18 levels to serum lipid and glucose concentrations in an apparently healthy adult population. Horm Res, v. 60, n. 1, p. 29-33, 2003.
88. BOSCH, M. et al. Circulating IL-18 concentration is associated with insulin sensitivity and glucose tolerance through increased fat-free mass. Diabetologia, v. 48, n. 9, p. 1841-3, 2005.
89. ESCOBAR-MORREALE, H. F. et al. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab, v. 89, n. 2, p. 806-11, 2004.
90. HUNG, J. et al. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol, v. 25, n. 6, p. 1268-73, 2005.
91. SUCHANEK, H. et al. High serum interleukin-18 concentrations in patients with coronary artery disease and type 2 diabetes mellitus. Eur Cytokine Netw, v. 16, n. 3, p. 177-85, 2005.
92. GIEDRAITIS, V. et al. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol, v. 112, n. 1-2, p. 146-52, 2001.
93. EVANS, J. et al. The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease. Eur J Endocrinol, v. 157, n. 5, p. 633-40, 2007.
94. KRETOWSKI, A. et al. Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes, v. 51, n. 11, p. 3347-9, 2002.
95. KRETOWSKI, A.; KINALSKA, I. Serum levels of interleukin-18--a potential marker of cardiovascular death--could be determined by genetic predisposition. Circulation, v. 107, n. 22, p. e206-7, 2003.
96. ISHIMITSU, T. et al. Interferon gamma attenuates hypertensive renal injury in salt- sensitive Dahl rats. Hypertension, v. 19, n. 6, p. 804-8, 1992.
97. MONCADA, S. Nitric oxide: discovery and impact on clinical medicine. J R Soc Med, v. 92, n. 4, p. 164-9, 1999.
98. MIYAMOTO, Y. et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension, v. 32, n. 1, p. 3-8, 1998.
99. FERNANDEZ-REAL, J. M.; RICART, W. Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia, v. 42, n. 11, p. 1367-74, 1999.
100. FESTA, A. et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation, v. 102, n. 1, p. 42-7, 2000.
101. PRAVICA, V. et al. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol, v. 61, n. 9, p. 863-6, 2000.
102. TEGOSHI, H. et al. Polymorphisms of interferon-gamma gene CA-repeat and interleukin-10 promoter region (-592A/C) in Japanese type I diabetes. Hum Immunol, v. 63, n. 2, p. 121-8, 2002.
103. TSIAVOU, A. et al. Correlation between intracellular interferon-gamma (IFN- gamma) production by CD4+ and CD8+ lymphocytes and IFN-gamma gene polymorphism in patients with type 2 diabetes mellitus and latent autoimmune diabetes of adults (LADA). Cytokine, v. 31, n. 2, p. 135-41, 2005.
104. FROSSARD, P. M. et al. A study of five human cytokine genes in human essential hypertension. Molecular Immunology, v. 38, p. 969–976, 2001.
105. TONET, A. C. et al. Association between the -174 G/C promoter polymorphism of the interleukin-6 gene and cardiovascular disease risk factors in Brazilian older women. Braz J Med Biol Res, v. 41, n. 1, p. 47-53, 2008.
106. MORAES, C. F. et al. A common polymorphism in the renin angiotensin system is associated with differential outcome of antihypertensive pharmacotherapy prescribed to Brazilian older women. Clin Chim Acta, v. 396, n. 1-2, p. 70-5, 2008.
107. PAIVA, C. R. E. et al. Avaliação da Composição Corporal em Meninos Brasileiros: o Método da Impedância Bioelétrica. Revista Brasileira de Cineantropometria & Desempenho Humano, v. 4, n. 1, p. 37-45, 2002.
108. MCARDLE, W. D.; KATCH, F. I; KATCH, V. L. Fundamentos de fisiologia do exercício. 2002, Rio de Janeiro: Guanabara Koogan S.A.
109. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report on the National Cholesterol Education Program (NCEP) JAMA, v. 285, n. 19, p. 2486-97, 2001.
110. The IDF consensus worldwide definition of metabolic syndrome. Avaliable from: http://www.idf.org.
111. ROESCHLAU, P.; BERNT, E.; GRUBER, W. A. Clin. Chem. Clin. Biochem. v. 12, p. 226, 1974.
112. ALLAIN, C. C.; POON, L. S.; CHAN, C. S.; RICHMOND, W. Clinical. Chemistry. v. 20, p. 470-475, 1974.
113. KIMBERLY, M.; LEARY, E.; COLE, T.; WAYMACK, P. Selection, validation, standardization and performance of designated comparision method for HDL- Cholesterol for use in the cholesterol reference method laboratory network. Clin.Chem., v. 45, p. 1803-1812, 1999.
114. WAHLEFELD, A. W.; BERGMEYER, H. U. Methods of enzimatic analysis. New York: Academic Press inc. 1831 f. 1974.
115. FRIEDWALD, W.T.; LEVY, R.I.; FRIEDRICKSON, D.S. Estimation of the concentration of Low–Density-Lipoprotein Cholesterol in plasma, without use of the preparative ultra centrifugue. Clin Chem, v. 18, p. 499-502, 1972.
116. TRINDER, P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol, v. 22, n. 2, p. 158-61, 1969.
117. MILLER, S. A.; DYKES, D. D.; POLESKY, H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, v. 16, n. 3, p. 1215, 1988.
118. CARLOS, C. D. Desenvolvimento e validação de um sistema para genotipagem em multiplex de polimorfismos causais em genes de citocinas pró-inflamatórias. Brasília 2008. 46 f. Trabalho de Conclusão de Curso (Faculdade de Ciências da Educação e Saúde - Biomedicina) - Universidade Católica de Brasília, Brasília, 2008.
119. COSTA, A. M. et al. Interleukin-6 (G-174C) and tumour necrosis factor-alpha (G- 308A) gene polymorphisms in geriatric patients with chronic periodontitis. Gerodontology, v. 27, n. 1, p. 70-5, jun, 2009.
120. LINS, T. C. L. Impacto da Miscigenação na Aplicação do HapMap para a População Brasileira Avaliado nos Genes PTPN22 e VDR. Brasília. 2007. 196 f. Dissertação (Mestrado em Ciências Genômicas e Biotecnologia) - Universidade Católica de Brasília, Brasília, 2007.
121. BONILLA, C. et al. Ancestral proportions and their association with skin pigmentation and bone mineral density in Puerto Rican women from New York city. Hum Genet, v. 115, n. 1, p. 57-68, 2004.
122. FERNANDEZ, J. R. et al. Association of African genetic admixture with resting metabolic rate and obesity among women. Obes Res, v. 11, n. 7, p. 904-11, 2003. 123. SHRIVER, M. D. et al. Large-scale SNP analysis reveals clustered and continuous
patterns of human genetic variation. Hum Genomics, v. 2, n. 2, p. 81-9, 2005.
124. SMITH, M. W. et al. A high-density admixture map for disease gene discovery in african americans. Am J Hum Genet, v. 74, n. 5, p. 1001-13, 2004.
125. PEDROSA, M. A. F. Composição genética de quatros populações remanescentes de quilombos do Brasil com base em microssatélites e marcadores de ancestralidade. Dissertação (Mestrado em Biologia Molecular) Departamento de Biologia Celular, Universidade de Brasília, Brasília, 2006.
126. ERSHLER, W. B.; KELLER, E. T. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med, v. 51, n. p. 245-70, 2000. 127. PARK, Y. W. et al. The metabolic syndrome: prevalence and associated risk factor
findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med, v. 163, n. 4, p. 427-36, 2003. 128. HODGE, A. M.; ZIMMET, P. Z. The epidemiology of obesity. Baillieres Clin
Endocrinol Metab, v. 8, n. 3, p. 577-99, 1994.
129. DOUGLAS, J. G.; THIBONNIER, M.; WRIGHT JUNIOR, J. T. Essential hypertension: racial/ethnic differences in pathophysiology. J Assoc Acad Minor Phys, v. 7, n. 1, p. 16-21, 1996.
130. LINS, T. C. et al. Genetic composition of Brazilian population samples based on a set of twenty-eight ancestry informative SNPs. Am J Hum Biol, v. 22, n. 2, p. 187-92, 2010.
131. CALLEGARI-JACQUES, S. M. et al. Historical genetics: spatiotemporal analysis of the formation of the Brazilian population. Am J Hum Biol, v. 15, n. 6, p. 824-34, 2003.
132. DEO, R. C. et al. Genetic differences between the determinants of lipid profile phenotypes in African and European Americans: the Jackson Heart Study. PLoS Genet, v. 5, n. 1, p. e1000342, 2009.
133. LE CAM, A.; LEGRAVEREND, C. Transcriptional repression, a novel function for 3' untranslated regions. Eur J Biochem, v. 231, n. 3, p. 620-7, 1995.
134. GRZYBOWSKA, E. A.; WILCZYNSKA, A.; SIEDLECKI, J. A. Regulatory functions of 3'UTRs. Biochem Biophys Res Commun, v. 288, n. 2, p. 291-5, 2001. 135. MORAHAN, G. et al. Linkage disequilibrium of a type 1 diabetes susceptibility locus
with a regulatory IL12B allele. Nat Genet, v. 27, n. 2, p. 218-21, 2001.
136. DAVOODI-SEMIROMI, A.; YANG, J. J.; SHE, J. X. IL-12p40 is associated with type 1 diabetes in Caucasian-American families. Diabetes, v. 51, n. 7, p. 2334-6, 2002. 137. YILMAZ, V.; YENTUR, S. P.; SARUHAN-DIRESKENELI, G. IL-12 and IL-10 polymorphisms and their effects on cytokine production. Cytokine, v. 30, n. 4, p. 188- 94, 2005.
138. BERGHOLDT, R. et al. Genetic and functional evaluation of an interleukin-12 polymorphism (IDDM18) in families with type 1 diabetes. J Med Genet, v. 41, n. 4, p. e39, 2004.
139. GRALLERT, H. et al. IL-6 promoter polymorphisms and quantitative traits related to the metabolic syndrome in KORA S4. Exp Gerontol, v. 41, n. 8, p. 737-45, 2006. 140. HUTH, C. et al. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis
of individual participants' data from 21 studies. Diabetes, v. 55, n. 10, p. 2915-21, 2006.
141. VOZAROVA, B. et al. The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet, v. 112, n. 4, p. 409-13, 2003.
142. FISHMAN, D. et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic- onset juvenile chronic arthritis. J Clin Invest, v. 102, n. 7, p. 1369-76, 1998.
143. OLIVIERI, F. et al. The -174 C/G locus affects in vitro/in vivo IL-6 production during aging. Exp Gerontol, v. 37, n. 2-3, p. 309-14, 2002.
144. RIVERA-CHAVEZ, F. A. et al. Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock, v. 20, n. 3, p. 218-23, 2003.
145. HULKKONEN, J. et al. Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren's syndrome and correlate with the clinical manifestations of the disease. Rheumatology (Oxford), v. 40, n. 6, p. 656-61, 2001.
146. CARDELLINI, M. et al. C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. Diabetes Care, v. 28, n. 8, p. 2007-12, 2005. 147. FERNANDEZ-REAL, J. M.; RICART, W. An increased proinflammatory activity is
inherent in insulin resistance. Med Clin (Barc), v. 115, n. 5, p. 185-9, 2000.
148. CARVALHO, M. H. C.; COLAÇO, A. L.; FORTES, Z. B. Citocinas, Disfunção Endotelial e Resistência à Insulina. Arq Bras Endocrinol Metab, v. 50, n. 2, p. 304- 312, 2006.
149. SENN, J. J. et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes, v. 51, n. 12, p. 3391-9, 2002.
150. SENN, J. J. et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem, v. 278, n. 16, p. 13740-6, 2003.
151. STITH, R. D.; LUO, J. Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock, v. 44, n. 4, p. 210-5, 1994.
152. TSIGOS, C. et al. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab, v. 82, n. 12, p. 4167-70, 1997.
153. FERNANDEZ-REAL, J. M. et al. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab, v. 85, n. 3, p. 1334-9, 2000.
154. PICKUP, J. C. et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia, v. 40, n. 11, p. 1286-92, 1997.
155. NONOGAKI, K. et al. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology, v. 136, n. 5, p. 2143-9, 1995.
156. WINKLER, G. et al. Increased interleukin-12 plasma concentrations in both, insulin- dependent and non-insulin-dependent diabetes mellitus. Diabetologia, v. 41, n. 4, p. 488, 1998.
157. LAMONT, A. G.; ADORINI, L. IL-12: a key cytokine in immune regulation. Immunol Today, v. 17, n. 5, p. 214-7, 1996.
158. RINCON, M. et al. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med, v. 185, n. 3, p. 461-9, 1997.
159. MERBERG, D. M.; WOLF, S. F.; CLARK, S. C. Sequence similarity between NKSF and the IL-6/G-CSF family. Immunol Today, v. 13, n. 2, p. 77-8, 1992.
160. GEARING, D. P.; COSMAN, D. Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor. Cell, v. 66, n. 1, p. 9-10, 1991.
161. COLLISON, L. W.; VIGNALI, D. A. Interleukin-35: odd one out or part of the family? Immunol Rev, v. 226, n. p. 248-62, 2008.
162. NGUYEN, K. B. et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science, v. 297, n. 5589, p. 2063-6, 2002.
163. BACON, C. M. et al. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc Natl Acad Sci U S A, v. 92, n. 16, p. 7307-11, 1995.
164. JACOBSON, N. G. et al. Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J Exp Med, v. 181, n. 5, p. 1755-62, 1995.
165. KAPLAN, M. H. et al. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature, v. 382, n. 6587, p. 174-7, 1996.
166. THIERFELDER, W. E. et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature, v. 382, n. 6587, p. 171-4, 1996.